Clinical Neuroscience and Neurogenetics

About Conference

Sessions And Tracks

Track 1: Genetics and Neurogenetics

• Molecular Genetics of Neurological Disorders
• Genetic Variation and Neurological Disease
• Neurogenetic Disorders and Inherited Conditions
• Genotype–Phenotype Correlations
• Genetic Characteristics of the Nervous System

Track 2: Neurodegeneration

• Mechanisms of Neurodegenerative Diseases
• Alzheimer's sickness and Parkinson’s Disease
• Neurodegeneration and Neuronal Dysfunction
• Cellular and Molecular Mechanisms
• Emerging Therapeutic Strategies

Track 3: Neuroimmunology and Neuroinfection

• Neuroinflammation and Immune-Mediated Disorders
• Multiple Sclerosis and Autoimmune Neuropathies
• neuroscience Genetics
• Neurovirology and Neuroinfectious Diseases
• Novel Therapeutic and Drug Development Approaches

Track 4: Neurological Diagnostics and Neuroimaging

• Advanced Neurological Examination
• Brain Imaging and Neuroimaging
• MRI, CT and PET Imaging
• Angiography and Diagnostic Procedures
• Emerging Diagnostic Technologies

Track 5: Neurorehabilitation and Genetic Counseling

• Advances in Neurological Rehabilitation
• Acute and Occupational Rehabilitation
• Rehabilitation for Neurogenetic Disorders
• Genetic Counseling and Risk Assessment
• Patient-Centered Neurological Care

Track 6: Alzheimer’s Disease and Dementia

• Alzheimer’s Disease and Cognitive Decline
• Dementia Diagnosis and Prevention
• Memory Disorders and Neurological Dysfunction
• Brain Aging and Neurodegeneration
• Vascular Dementia and Stroke-Related Cognitive Impairment

Track 7: Neuropharmacology and Therapeutics

• Principles of Neuropharmacology
• CNS Receptors and Novel Therapeutics
• Drug Development for Neurological Disorders
• Drug Targeting and Therapeutic Strategies
• Emerging Pharmacological Approaches

Track 8: Pediatric Neurology and Neurogenetics

• Pediatric Neurogenetic Disorders
• Neurodevelopmental Disorders
• Genetic and Chromosomal Conditions
• Perinatal Neurology and Child Health
• Neonatal Neurological Disorders

Track 9: Neuro-Ophthalmology

• Neurological Causes of Visual Dysfunction
• Optic Nerve Disorders
• Neuro-Ophthalmic Manifestations
• Neuro-Ophthalmology in Multiple Sclerosis and Stroke
• Diagnosis and Treatment of Neuro-Ophthalmic Disorders

Track 10: Neuro-Oncology and Neurology

• Primary Tumors of the Nervous System
• Brain and Spinal Cord Tumors
• Metastatic Neurological Tumors
• Molecular and Genetic Aspects of Neuro-Oncology
• Advances in Diagnosis and Treatment

Track 11: Neuropathology

• Molecular and Cellular Neuropathology
• Neurocytology and Tissue Pathology
• Metabolic and Nutritional Neurological Disorders
• Myopathology
• Peripheral Neuropathies and Neuromuscular Disorders

Track 12: Neurocardiology and Stroke

• Neurocardiac Interactions
• Stroke Mechanisms and Management
• Heart–Brain Axis
• Neurovascular Disorders
• Arrhythmias and Autonomic Neural Regulation
• Clinical Case Studies in Stroke and Neurocardiology

Track 13: Neurochemistry and Molecular Neuroscience

• Neurotransmitters and Neuropeptides
• Molecular Neuroscience
• Chemical Neurobiology
• Molecular Mechanisms of the Nervous System
• Neuroinflammation and Immunoneurochemistry
• Neural Control and Neurochemical Signaling

Track 14: Nursing and Neuroscience

• Neurological Nursing Care
• Neurotrauma and Neurosurgical Nursing
• Neurological Critical and Intensive Care
• Long-Term Neurological Conditions
• Patient-Centered Neurological Support

Track 15: Ataxia and Movement Disorders

• Cerebellar Ataxia
• Sensory and Vestibular Ataxia
• Genetic Ataxia
• Neurological Causes of Ataxia
• Diagnosis and Management of Movement Disorders

Track 16: Neurogenetic Research and Emerging Technologies

• Advances in Neurogenetic Research
• Genome-Wide Studies and Genetic Analysis
• Next-Generation Sequencing
• Recombinant DNA and Molecular Technologies
• Neurobiology of Autism
• Genetic Mechanisms of Neurodegenerative Diseases

Track 17: Psychiatry, Psychology and Neuroscience

• Neuropsychiatry and Behavioral Neuroscience
• Clinical Psychology and Mental Health
• Psychotherapy and Counseling
• Cognitive and Behavioral Disorders
• Neurobiological Perspectives in Psychiatry

Track 18: Epilepsy and Seizure Disorders

• Genetics and Causes of Epilepsy
• Types and Classification of Epilepsy
• Epilepsy Across Age Groups
• Diagnosis and Clinical Management
• Emerging Therapies and Clinical Case Studies

Track 19: Neurological Evaluation, Treatment and Management

• Neurological Evaluation and Diagnosis
• Treatment Strategies for Neurogenetic Disorders
• Clinical Trials and Translational Research
• Symptomatic and Neuroprotective Therapies
• Patient Care and Disease Management
• Emerging Therapeutic Approaches

Market Analysis

The 38th Conference on Clinical Neuroscience and Neurogenetics, taking place on March 24–25, 2027, in Geneva, Switzerland, focuses on the growing field of neuroscience and neurogenetics under the theme “Transforming Neurological Care Through Neuroscience, Genetics, and Innovation.”

The conference addresses key areas including neurogenetics, neurodegeneration, neuroimmunology, diagnostic tools, neuropharmacology, pediatric neurology, neuro-ophthalmology, neuro-oncology, neuropathology, neurocardiology and neuroimaging, neurochemistry, and neurogenetic research.

The neurodegenerative disease sector continues to receive significant research attention due to the growing aging population and increasing prevalence of neurological disorders. The provided data identifies Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, and ALS among important neurodegenerative conditions and highlights the continuing need for effective diagnostic and therapeutic approaches.

Key Market Drivers

• Growing prevalence of neurological and neurodegenerative disorders
• Increasing aging population and associated neurological conditions
• Advances in neurogenetic and molecular research
• Demand for improved diagnostic tools and imaging technologies
• Development of innovative drugs and therapeutic approaches
• Rising international collaboration in neuroscience and neurology

Neurogenetics | Neurodegeneration | Neuroimmunology | Diagnostics | Neuropharmacology | Pediatric Neurology | Neuro-Oncology | Neuroimaging | Neurocardiology | Neurochemistry | Genetic Research

The conference will provide a platform for researchers, clinicians, neurologists, geneticists, and healthcare professionals to exchange knowledge and discuss emerging developments across these rapidly advancing fields.

Neurodegenerative diseases are related to neurons present in human brain. The global neurodegenerative disease market is expected to rise at a CAGR of 4.90% during the forecast period 2016-2023. The major driver of the global neurodegenerative disease market is rising aging population globally. According to the National Institute on Aging, 6.5 million people aged 65 years and above globally. The worldwide population of the oldest people of age 80 and above is anticipated to rise by thrice that is from 126.5 million to 446.6 million during 2015 to 2050.

Since the nature of the neurodegenerative diseases is complex, there are many factors that prompt the growth of the global neurodegenerative disease market. Some of the key factors include the rapid growth of neurodegenerative diseases across the globe and raising awareness about mental disorders. The rising geriatric population across the world increases the chances of occurrence of neurological diseases. Researchers are being conducted to find an effective treatment for neurodegenerative diseases can fuel the growth of this market. The major restraining factor of the global neurodegenerative disease market is the lack of effective drugs and therapies to treat the disease. Also, the lack of information about the causes of these neurodegenerative diseases hinders the development of drugs and treatment for the same.

With the advanced aging of the ‘baby boom’ generation in many Western countries, age-related neurodegenerative disorders like dementia and Parkinson’s disease (PD) are becoming a major healthcare problem. Approximately 10% of adults above 65 years and 47% of adults above 85 years suffer from dementia, 1–3% of the population above 60 years currently suffers from PD, while (partly) genetically determined neurodegenerative disorders like Huntington’s chorea or amyotrophic lateral sclerosis (ALS) affect a considerable number of subject.

In Switzerland, 8% of Neuro researchers are going. In the USA 11% of Neuro research is going.